Oncolytics Biotech presents ASCO 2026 data from pelareorep trials in GI tumors

• Oncolytics Biotech flagged new translational results for its investigational immunotherapy pelareorep, with data from the GOBLET and AWARE-1 studies scheduled for presentation at the ASCO Annual Meeting in Chicago on May 30, 2026.
• The analyses point to an immune-activation sequence in which treatment amplifies existing tumor-reactive immune cells, linking that response to tumor shrinkage signals in advanced pancreatic cancer.
• Findings also suggest activity in hard-to-treat KRAS-driven disease, including expansion of mutant KRAS-specific T-cell clones, supporting the drug’s positioning across gastrointestinal tumors.
• In early-stage breast cancer, tumor biopsies indicated increased antiviral and immune signaling consistent with inflammatory immune remodeling, including features associated with tertiary lymphoid structure formation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605220900PRIMZONEFULLFEED9725137) on May 22, 2026, and is solely responsible for the information contained therein.